543 cancer drug prices reduced effective November 9
The short version
- The National Pharmaceutical Pricing Authority released revised maximum retail prices for 543 brands of anti-cancer medicines.
- The new prices will take effect from November 9.
- Dr Reddy's Laboratories' Azacytin, a 100 mg azacitidine injection, will cost ₹1,495.04, down from ₹6,337.
- Jan Swasthya Abhiyan India says controlling trade margins is not enough; affordability must be based on medical need.
- Health experts say the price cuts expose previous excessive pricing of cancer drugs.
What we don’t know yet
- What specific criteria were used to determine the new prices?
- How many of the 543 brands had price reductions above or below the average?
- What is the expected impact on pharmaceutical companies' profits?
Does this story matter to you?
Coverage compared
How coverage grew
First reported by The Hindu Sharp cuts in price of cancer drugs expose excessive pricing, say health experts
Hindustan Times Cancer drug prices slashed for 543 brands; new rates from November 9